Brain Imaging News
-
EMOTIV Enlists Two Machine Learning Heavyweights as AI Takes Aim at the Human Brain
EMOTIV, the bioinformatics pioneer advancing understanding of the human brain using electroencephalography (EEG), today added two renowned scientists to its executive leadership team, naming Dr. Gary William Flake as Chief Technology Officer (CTO) and Dr. Scott Rickard as Chief AI Scientist. The new hires underscore EMOTIV’s strategic objectives to meet the quickening pace of advancements ...
By Emotiv Inc.
-
SpinTech CEO Presents STAGE at MedTech Strategist Innovation San Francisco 2021
Ward Detwiler, our President & CEO, had the opportunity to speak about how STAGE is innovating the world of MR at MedTech Strategist Innovation 2021. ...
-
Pivalate’s additional data released from positive Phase II imaging trial in brain metastases
Sydney, Australia - November 23, 2022 - Radiopharm Theranostics (ASX:RAD), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce that Imperial College London has released additional data related to the F-18 Pivalate (RAD 101) Phase 2a imaging trial in patients with brain metastases. High contrast images (see below) ...
-
Oxford Brain Diagnostics’ grey matter quality measure selected as secondary outcome for Alzheimer’s Phase 2 clinical trial
Approximately 201 patients will be enrolled to study the XPro™ intervention. The objectives of this study are to determine the safety, tolerability, and efficacy of XPro™ in patients with mild AD. Oxford, UK, 29th March 2022. Oxford Brain Diagnostics, a software company focused on developing diagnostics that identify changes in the brain at a cellular level, today announced that ...
-
22 high-level BRAIN QUICK EEG systems for Poland
Together with our distributor Ma-J-er, we installed 22 BRAIN QUICK Video EEG systems with Ambulatory and Sleep options in Poland and trained the local users on the systems. This great innovation for Polish hospitals could be realized thanks to the generosity of the national charity organization “WOSP”. Charity for the best possible medical care for people in Poland. Founded in 1993, ...
-
Longeveron Publishes Peer Reviewed Study of Phase 1 Trial Results of Lomecel-B for Alzheimer’s Disease in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association
Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biopharma company developing cellular therapies for aging-related illnesses, chronic disorders, and other specific life-threatening conditions, announced the publication of results from a Phase 1 trial testing Lomecel-B on patients with mild Alzheimer’s disease (AD) in Alzheimer’s & Dementia®: The Journal of the ...
-
Inscopix Expands Strategic Partnership with GRINTECH to Become Exclusive Global Supplier of GRIN lenses
Inscopix, Inc., a neuroscience company helping decode the brain for tomorrow’s treatments, announced that it is expanding its strategic supplier partnership with leading gradient index (GRIN) lens manufacturer GRINTECH GmbH to be the sole exclusive seller of GRIN lenses for neuroscience research applications. Inscopix offers innovative miniature-microscope (miniscope) based imaging ...
-
Qynapse to Present Symposium Oral and Poster presentations at AD/PD™ 2022 International Conference
PARIS, FRANCE, March 3, 2022, PRNewswire – Qynapse SAS, a medical technology company commercializing an FDA approved/CE cleared AI-powered neuroimaging software platform for central nervous system (CNS) disorders, is pleased to announce that a symposium oral presentation and a poster presentation will be delivered at the upcoming AD/PD™ 2022 International Conference on ...
By Qynapse
-
Qynapse to Present New Evidence on the Value of QyScore for the Diagnosis and Monitoring of Multiple Sclerosis at ACTRIMS Forum 2022
BOSTON, MA, February 14, 2022, PRNewswire – Qynapse Inc., a medical technology company commercializing an AI-powered neuroimaging software platform for central nervous system (CNS) disorders, is pleased to present 2 posters at the annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2022, on February 24-26, in West Palm Beach, FL. The posters ...
By Qynapse
-
AI ‘Fingerprinting’ Fights Back Against Hard-to-Detect Cancers
Hard-to-detect cancers like glioblastoma can have survival rates in the single-digit percentages and require elaborate techniques to detect, treat, and monitor. Reveal Surgical is working on changing that reality through its new, AI-based Sentry technology, which leverages a combination of AI and Raman spectroscopy to provide real-time tissue diagnostics during surgery for otherwise-invisible ...
-
Optina announces a US$2.1M investment from the Diagnostics Accelerator at the Alzheimer’s Drug Discovery Foundation (ADDF)
A collaborative research initiative supported by ADDF’s Co-Founder Leonard A. Lauder, Bill Gates, Jeff Bezos, MacKenzie Scott, the Dolby family, and the Charles and Helen Schwab Foundation, among others, to advance the most promising early diagnostics for Alzheimer’s disease. Optina, an innovative diagnostics company, leader in retinal imaging, brain health and systemic disease ...
-
M Health Fairview University of Minnesota Medical Center Receives First Hyperfine Portable MRI to Grow its Advanced Imaging Systems Offering
Hyperfine, Inc. (Nasdaq: HYPR) (“Hyperfine”), creator of the first U.S. Food and Drug Administration (“FDA”) cleared portable magnetic resonance imaging (“MRI”)TM device, Swoop®, is proud to announce that M Health Fairview is deploying a Swoop system in the emergency room (ER), intensive care unit (ICU) and post anesthesia environments at M Health Fairview ...
By Hyperfine
-
Another good news for Deep01! Taiwan`s first AI product obtained marketing approval from Japan`s FDA
DeepCT - Intracranial Hemorrhage (ICH) AI Detection Software - developed by Taiwan's high-profile AI start-up team Deep01 - has obtained the marketing approval of Japan's PMDA, which is the first deep learning software officially licensed by Japan in Taiwan , marking a new milestone in Taiwan's AI medical output. Japan has the world's most aging population, and with advanced medical development, ...
-
Hyperfine Closes Business Combination with HealthCor Catalio Acquisition Corp and Liminal Sciences, Will Begin Trading under the Ticker “HYPR” on the Nasdaq Global Market
Business combination results in over $160 million in gross cash proceeds to Hyperfine Funds to catalyze commercial expansion of the world’s first FDA-cleared portable MRI systemTM and additional organic growth initiatives Hyperfine to begin trading on Nasdaq under ticker “HYPR” Hyperfine Inc., the groundbreaking medical device company that created Swoop®, the ...
By Hyperfine
-
Arterys Partners With Cercare Medical to Offer Advanced Perfusion Brain CT and MR Imaging Analysis Accelerating Access to Deep, Fast, and Reliable Insights
SAN FRANCISCO, November 29, 2021 (Newswire.com) - Arterys, the world's leading vendor-neutral AI platform, today announced its partnership with Cercare Medical to make their AI-powered imaging solution, Cercare Perfusion, available on the Arterys Platform. Arterys has fully integrated the Cercare Perfusion solution which will be available via its FDA-cleared and CE marked MICA platform to its ...
By Arterys Inc.
-
Arterys Partners With Combinostics to Accelerate Accurate and Consistent Evaluations of Patients With Neurodegenerative Disease and Multiple Sclerosis
SAN FRANCISCO, November 26, 2021 (Newswire.com) - Arterys, the world's leading vendor neutral AI platform, today announced its partnership with Combinostics to make their AI imaging solution, cNeuro® available on the Arterys Platform. This partnership enables Arterys to have the most comprehensive Neuro AI suite on the market covering a broad set of applications in neuroradiology. Arterys ...
By Arterys Inc.
-
Qynapse Unveils its New Brand and Latest Developments in Neuroimaging AI Innovation at the 2021 RSNA Meeting in Chicago
BOSTON, MA, November 22, 2021, PRNewswire – Qynapse Inc., a medical technology company commercializing an artificial intelligence (AI)-powered neuroimaging software platform for central nervous system (CNS) disorders, will unveil its new brand and latest AI developments as a key exhibitor in the AI Showcase at the 107th Radiology Society of North America (RSNA) Annual Meeting, from ...
By Qynapse
-
Qynapse to Sponsor and Present New Data on QyPredict at Clinical Trials on Alzheimer’s Disease Conference (CTAD 2021)
BOSTON, MA, November 4, 2021, PRNewswire – Qynapse Inc., a medical technology company commercializing an AI-powered neuroimaging software platform for central nervous system (CNS) disorders, is pleased to sponsor the 14th Clinical Trials on Alzheimer’s Disease conference (CTAD) to be held from November 9-12, 2021, in Boston, MA. Qynapse will present new results on Qypredict®, ...
By Qynapse
-
Revolutionary non-invasive technology supporting early diagnosis of Parkinson’s disease showcased at MEDICA 2021
Manus Neurodynamica Limited (“Manus”), who develop and market products and technologies for neuromotor assessment, will be joining the ABHI UK Pavilion at MEDICA 2021 (15 – 18 November 2021) to launch their revolutionary non-invasive technology that supports an earlier and more accurate diagnosis of dementias and cognitive impairment. The NeuroMotor Pen (NMP) is a unique, ...
-
Optina Diagnostics Closes an Oversubscribed Series-A Round of CA$24.8 million
2021 Optina, an innovative diagnostics company leading the field of Retinal Imaging, Brain Health and Systemic Diseases Diagnostics, announced today the closing of an CA$24.8 million Series A round of funding. Optina’s Retinal Deep Phenotyping™ platform obtained FDA Breakthrough Device Designation status in 2019 for its non-invasive and more accessible test to improve diagnosis ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you